Research ArticleSofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Under a Creative Commons license
open access
Graphical abstract
Keywords
Direct-acting antiviral
ESRD
Severe renal impairment
Chronic hepatitis C infection
HCV, SVR12, drug safety
Cited by (0)
© 2019 European Association for the Study of the Liver. Published by Elsevier B.V.